Andrew J. Gartland,Sue Li,John McNevin,Georgia D. Tomaras,Raphael Gottardo,Holly Janes,Youyi Fong,Daryl Morris,Daniel E. Geraghty,Gustavo H. Kijak,Paul T. Edlefsen,Nicole Frahm,Brendan B. Larsen,Sodsai Tovanabutra,Eric Sanders-Buell,Allan C. deCamp,Craig A. Magaret,Hasan Ahmed,Jodie P. Goodridge,Lennie Chen,Philip Konopa,Snehal Nariya,Julia N. Stoddard,Kim Wong,Hong Zhao,Wenjie Deng,Brandon S. Maust,Meera Bose,Shana Howell,Adam Bates,Michelle Lazzaro,Annemarie O'Sullivan,Esther Lei,Andrea Bradfield,Grace Ibitamuno,Vatcharain Assawadarachai,Robert J. O'Connell,Mark S. Desouza,Sorachai Nitayaphan,Supachai Rerks-Ngarm,Merlin L. Robb,John Sidney,Alessandro Sette,Susan Zolla-Pazner,David Montefiorl,M. Juliana McElrath,James I. Mullins,Jerome H. Kim,Peter B. Gilbert,Tomer Hertz

Abstract:ABSTRACT The RV144 HIV-1 vaccine trial demonstrated partial efficacy of 31% against HIV-1 infection. Studies into possible correlates of protection found that antibodies specific to the V1 and V2 (V1/V2) region of envelope correlated inversely with infection risk and that viruses isolated from trial participants contained genetic signatures of vaccine-induced pressure in the V1/V2 region. We explored the hypothesis that the genetic signatures in V1 and V2 could be partly attributed to selection by vaccine-primed T cells. We performed a T-cell-based sieve analysis of breakthrough viruses in the RV144 trial and found evidence of predicted HLA binding escape that was greater in vaccine versus placebo recipients. The predicted escape depended on class I HLA A*02- and A*11-restricted epitopes in the MN strain rgp120 vaccine immunogen. Though we hypothesized that this was indicative of postacquisition selection pressure, we also found that vaccine efficacy (VE) was greater in A*02-positive (A*02 + ) participants than in A*02 − participants (VE = 54% versus 3%, P = 0.05). Vaccine efficacy against viruses with a lysine residue at site 169, important to antibody binding and implicated in vaccine-induced immune pressure, was also greater in A*02 + participants (VE = 74% versus 15%, P = 0.02). Additionally, a reanalysis of vaccine-induced immune responses that focused on those that were shown to correlate with infection risk suggested that the humoral responses may have differed in A*02 + participants. These exploratory and hypothesis-generating analyses indicate there may be an association between a class I HLA allele and vaccine efficacy, highlighting the importance of considering HLA alleles and host immune genetics in HIV vaccine trials. IMPORTANCE The RV144 trial was the first to show efficacy against HIV-1 infection. Subsequently, much effort has been directed toward understanding the mechanisms of protection. Here, we conducted a T-cell-based sieve analysis, which compared the genetic sequences of viruses isolated from infected vaccine and placebo recipients. Though we hypothesized that the observed sieve effect indicated postacquisition T-cell selection, we also found that vaccine efficacy was greater for participants who expressed HLA A*02, an allele implicated in the sieve analysis. Though HLA alleles have been associated with disease progression and viral load in HIV-1 infection, these data are the first to suggest the association of a class I HLA allele and vaccine efficacy. While these statistical analyses do not provide mechanistic evidence of protection in RV144, they generate testable hypotheses for the HIV vaccine community and they highlight the importance of assessing the impact of host immune genetics in vaccine-induced immunity and protection. (This study has been registered at ClinicalTrials.gov under registration no. NCT00223080.)

Achieving intracellular cytokine staining assay concordance on two continents to assess HIV vaccine-induced T-cell responses

Standardization of cytokine flow cytometry assays

SWIFT clustering analysis of intracellular cytokine staining flow cytometry data of the HVTN 105 vaccine trial reveals high frequencies of HIV-specific CD4+ T cell responses and associations with humoral responses

Vaccination with Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

Optimization and Qualification of a Memory B-cell ELISpot for the Detection of Vaccine-Induced Memory Responses in HIV Vaccine Trials.

HIV Diagnostics and Vaccines: It Takes Two to Tango

Comparing HIV Vaccine Immunogenicity across Trials with Different Populations and Study Designs

Immune-correlates Analysis of an HIV-1 Vaccine Efficacy Trial.

HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines

Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology Advanced Technology Laboratories

Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.

Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses

Effective B cell activation in vitro during viremic HIV-1 infection with surrogate T cell stimulation

Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial.

Baseline Circulating Activated TFH and Tissue-Like Exhausted B Cells Negatively Correlate With Meningococcal C Conjugate Vaccine Induced Antibodies in HIV-Infected Individuals

Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells

Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories

Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals

Development of an immunoassay for differentiating human immunodeficiency virus infections--from vaccine-induced immune response in Tiantan vaccine trials in China.

Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein